oxybutynin has been researched along with Bilateral Headache in 11 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This will be an open-label randomized, controlled trial conducted at Women's College Hospital comparing five formulations of nitrates for their effects on bone turnover markers and headache." | 5.17 | Nitrates and bone turnover (NABT) - trial to select the best nitrate preparation: study protocol for a randomized controlled trial. ( Bucur, RC; Cummings, SR; Hamilton, CJ; Jamal, SA; Reid, LS, 2013) |
| " Extended-release formulations of oxybutynin at 10 mg/d or tolterodine at 4 mg/d were given for 12 weeks to women with 21 to 60 urge urinary incontinence (UUI) episodes per week and an average of 10 or more voids per 24 hours." | 5.10 | Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. ( Appell, RA; Diokno, AC; Dmochowski, RR; Gburek, BM; Kell, SH; Klimberg, IW; Sand, PK, 2003) |
| " The objective of the present study was to determine the pharmacokinetic characteristics and tolerability of rotigotine transdermal patch after repeated-dose application in healthy male and female Korean subjects." | 2.80 | Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers. ( Andreas, JO; Braun, M; Cawello, W; Elshoff, JP; Jang, IJ; Kim, BH; Kim, JR; Soo Lim, K; Yu, KS, 2015) |
| " This study determined whether application of the AP to three different anatomical sites (lower abdomen, buttock and upper torso) influences the pharmacokinetic profile of EE and levonorgestrel (LNG)." | 2.78 | Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. ( Archer, DF; Foegh, M; Rubin, A; Stanczyk, FZ, 2013) |
| " Primary safety outcomes included occurrence of adverse events and dropouts." | 2.76 | Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. ( Beneš, H; Ferini-Strambi, L; Fichtner, A; García-Borreguero, D; Högl, B; Kohnen, R; Oertel, W; Poewe, W; Schollmayer, E; Stiasny-Kolster, K; Trenkwalder, C, 2011) |
| " Saliva output was measured objectively before dosing with each treatment and at 0." | 2.70 | A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. ( Appell, RA; Chancellor, MB; Gupta, SK; Sathyan, G, 2001) |
| " The maximum steady-state drug concentration and area under the concentration curve from time 0 on day 5 (t = 0) to the 24-hours sample on day 6 were 514 ng/mL (95% CI 439 to 603 ng/mL) and 9." | 1.48 | A Pharmacokinetic Study of an Ibuprofen Topical Patch in Healthy Male and Female Adult Volunteers. ( Bhatt, A; Connolly, MP; Lewis, F, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diokno, AC | 1 |
| Appell, RA | 2 |
| Sand, PK | 1 |
| Dmochowski, RR | 1 |
| Gburek, BM | 1 |
| Klimberg, IW | 1 |
| Kell, SH | 1 |
| Reiz, JL | 1 |
| Salem, P | 1 |
| Darke, AC | 1 |
| Chancellor, MB | 1 |
| Sathyan, G | 1 |
| Gupta, SK | 1 |
| Zhou, W | 1 |
| Lv, C | 1 |
| Zhang, Q | 1 |
| Zong, S | 1 |
| Wang, M | 1 |
| Lewis, F | 1 |
| Connolly, MP | 1 |
| Bhatt, A | 1 |
| Bucur, RC | 1 |
| Reid, LS | 1 |
| Hamilton, CJ | 1 |
| Cummings, SR | 1 |
| Jamal, SA | 1 |
| Kim, BH | 1 |
| Yu, KS | 1 |
| Jang, IJ | 1 |
| Soo Lim, K | 1 |
| Kim, JR | 1 |
| Elshoff, JP | 1 |
| Andreas, JO | 1 |
| Braun, M | 1 |
| Cawello, W | 1 |
| Oertel, W | 1 |
| Trenkwalder, C | 1 |
| Beneš, H | 1 |
| Ferini-Strambi, L | 1 |
| Högl, B | 1 |
| Poewe, W | 1 |
| Stiasny-Kolster, K | 1 |
| Fichtner, A | 1 |
| Schollmayer, E | 1 |
| Kohnen, R | 1 |
| García-Borreguero, D | 1 |
| Rapoport, AM | 1 |
| Stanczyk, FZ | 1 |
| Archer, DF | 1 |
| Rubin, A | 1 |
| Foegh, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of the Efficacy and Tolerability of DITROPAN XL and DETROL LA in the Treatment of Overactive Bladder[NCT00293839] | Phase 3 | 790 participants (Actual) | Interventional | Completed | |||
| Nitrates and Bone Turnover (NABT): Trial to Select the Best Nitrate Preparation[NCT01387672] | Phase 3 | 265 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Single-site, Randomized, Double-blind, Placebo-controlled, Repeated-dose Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in 2 Different Dosages (2 mg / 24 Hours [10 cm2], 4 mg / 24 Hours [20 cm2]) in Healthy Korean Subject[NCT01964573] | Phase 1 | 48 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| An Open-label Extension Trial to Determine Safety and Tolerability of Long-term Transdermal Application of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome[NCT00498186] | Phase 2 | 295 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Markers of Bone Formation:~Serum Procollagen type 1 amino- terminal propeptide (P1NP)~Serum Osteocalcin (OC)~Serum Bone-specific alkaline phosphatase (BALP)~Markers of Bone Resorption:~- Serum C-telopeptides of collagen cross-links (CTX)" (NCT01387672)
Timeframe: 3 months
| Intervention | Percent change from baseline (Mean) | |||
|---|---|---|---|---|
| P1NP | OC | BALP | CTX | |
| 0.3 Sublingual (Nitrostat 1) - Treatment Arm 4 | -6.126 | 1.046 | -7.000 | -0.666 |
| 0.6 Sublingual (Nitrostat 2) - Treatment Arm 5 | 2.941 | 1.033 | -3.686 | -1.380 |
| ISMO - Treatment Arm 1 | -4.627 | -3.244 | -5.023 | -5.844 |
| Ointment (Nitrol) - Treatment Arm 3 | -4.297 | -4.481 | -7.426 | -9.699 |
| Patch (Nitro-Dur) - Treatment Arm 2 | -0.405 | 3.796 | -0.541 | -1.025 |
| Placebo Ointment - Treatment Arm 6 | -1.635 | 4.247 | -1.648 | -1.783 |
"Severity of headaches. Subjects recorded the severity of headaches upon awakening every day during the run-in phase using a visual analogue scale (VAS). The scale is represented by a line (continuum) 10 cm long. Subjects were asked to make a vertical line along the continuum to indicate the severity of their headache each morning upon awakening. The score is recorded in cm from 0 to 10. A vertical line marked at 0 means no headache (score recorded = 0), a vertical line marked at 10 means a terrible headache (score recorded = 10)." (NCT01387672)
Timeframe: Run-in phase - 2 days
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| ISMO | Patch | Ointment | 0.3 Sublingual | 0.6 Sublingual | |
| Run-in Phase | 2.1 | 3.1 | 1.5 | 0.36 | 0.6 |
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment. (NCT00498186)
Timeframe: Up to five years
| Intervention | participants (Number) |
|---|---|
| Rotigotine | 93 |
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment. (NCT00498186)
Timeframe: Up to five years
| Intervention | participants (Number) |
|---|---|
| Rotigotine | 273 |
1 review available for oxybutynin and Bilateral Headache
| Article | Year |
|---|---|
The therapeutic future in headache.
Topics: Animals; Calcitonin Gene-Related Peptide; Cluster Headache; Dihydroergotamine; Forecasting; Headache | 2012 |
8 trials available for oxybutynin and Bilateral Headache
| Article | Year |
|---|---|
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
Topics: Administration, Oral; Aged; Benzhydryl Compounds; Constipation; Cresols; Delayed-Action Preparations | 2003 |
Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
Topics: Adolescent; Adult; Area Under Curve; Cross-Over Studies; Delayed-Action Preparations; Dizziness; Hea | 2007 |
A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate.
Topics: Adult; Area Under Curve; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Cross-Over Studies; | 2001 |
Pharmacokinetics, Pharmacodynamics, and Safety of Rasagiline Transdermal Patch: A Preliminary Study in Healthy Chinese Subjects.
Topics: Administration, Oral; Adolescent; Adult; Asian People; Dose-Response Relationship, Drug; Fasting; He | 2018 |
Nitrates and bone turnover (NABT) - trial to select the best nitrate preparation: study protocol for a randomized controlled trial.
Topics: Administration, Cutaneous; Administration, Sublingual; Age Factors; Biomarkers; Bone and Bones; Bone | 2013 |
Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers.
Topics: Adult; Asian People; Dopamine Agonists; Double-Blind Method; Female; Headache; Humans; Male; Middle | 2015 |
Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Double-Blind Method; Female; Follow-Up Studies; | 2011 |
Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch.
Topics: Abdomen; Adult; Buttocks; Cohort Studies; Contraceptive Agents, Female; Cross-Over Studies; Drug Com | 2013 |
2 other studies available for oxybutynin and Bilateral Headache
| Article | Year |
|---|---|
Detrol LA and Diropan XL for overactive bladder.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Clinical Trials as Topic; Cresols; Delayed-Action Pre | 2001 |
A Pharmacokinetic Study of an Ibuprofen Topical Patch in Healthy Male and Female Adult Volunteers.
Topics: Administration, Topical; Adult; Area Under Curve; Female; Headache; Healthy Volunteers; Humans; Ibup | 2018 |